SS-31 (Elamipretide) Peptide: Dubai Research Vial COA & Purity
SS-31 — also sold under the name elamipretide — is one of the most-studied mitochondrial-targeted peptides, which is exactly why careful sourcing matters. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Update History ▾
Research-use-only framing applied throughout in line with Remy editorial standards.
SS-31 (elamipretide) is a cardiolipin-targeting mitochondrial tetrapeptide with one of the deepest research datasets in its class — so the sourcing question really comes down to verified identity and purity, not hype. Remy Peptides currently lists SS-31 (Elamipretide) 10mg Vial as In stock, a 10mg · Lyophilized research vial with AED tiers shown around AED 250-300. The sections below cover identity, COA verification, and where the evidence stops — research-use framing throughout.
Verifying SS-31 before you order
SS-31 is sold under several names — you will see it written as SS31, as elamipretide, and in older literature as Bendavia or MTP-131 — so the first job of any sourcing check is confirming that the vial in front of you is the same molecule. The sections below walk through that identity check, how to confirm a lot-specific COA and HPLC purity, what the published research does and does not establish, and how researchers in Dubai and the UAE can verify a supplier before they buy an SS-31 vial.
For current product facts, start with SS-31 (Elamipretide) 10mg Vial. For the full cardiolipin-binding mechanism and trial dataset, read the SS-31 mitochondrial peptide research profile.
Compound Identity: What SS-31 Actually Is
SS-31 is the Szeto-Schiller designation for a synthetic aromatic-cationic tetrapeptide, also known by the clinical development name elamipretide and the earlier investigational names Bendavia and MTP-131. The sequence is D-Arg-2’6’-Dmt-Lys-Phe-NH2, with molecular formula C32H49N9O5 and a molecular weight of approximately 639.8 g/mol.
What makes SS-31 distinct as a research compound is its target. Rather than relying on the mitochondrial membrane potential to drive accumulation in the matrix, SS-31 concentrates at the inner mitochondrial membrane and binds cardiolipin — the anionic phospholipid that organises electron transport chain complexes at cristae junctions. Birk et al. (2013, J Am Soc Nephrol) characterised this dual-mode binding (electrostatic anchoring via the cationic residues plus hydrophobic insertion of the aromatic side chains) by NMR.[1] For a vendor page, the practical point is narrower: a listing that calls itself SS-31 should match this identity exactly, because elamipretide is a specific tetrapeptide, not a loose category. Identity precision is the first line of the COA check below.
Evidence Map and Translation Limits
SS-31 carries the broadest clinical dataset of any mitochondria-targeted research peptide, which makes the translation discipline more important, not less. The aging skeletal-muscle crossover study (Siegel et al., PNAS 2021) reported improved mitochondrial ATP production after a single infusion in older adults,[2] and the TAZPOWER Phase 2 trial in Barth syndrome reported a meaningful 6-minute-walk signal.[3] Those records describe a regulated drug program in defined patient populations — they do not convert a research-use catalog vial into a clinical product or support any consumer outcome claim.[4]
| Research layer | What the literature supports | What it means for sourcing |
|---|---|---|
| Identity | SS-31, elamipretide, Bendavia and MTP-131 name the same tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2). | A listing and COA should match this exact identity — that is how you rule out an alias mix-up. |
| Mechanism | Cardiolipin binding at the inner membrane is well characterised in cell and isolated-mitochondria models. | Explains how SS-31 behaves in cell and mitochondria models — not a basis for any outcome claim. |
| Evidence tier | Strongest human signals are Phase 2 RCTs (Barth syndrome) and small crossover work (aging muscle); most indications remain hypothesis-generating. | Treat the human data as early-stage; most uses remain hypothesis-generating. |
| Sourcing in the UAE | Local researchers need vial size, AED tier, stock, and a verifiable COA route. | Confirm vial size, AED tier, stock, and a lot-specific COA on the product page. |
Dubai/UAE Product Documentation
The live product page is the source of truth for price and stock. The table below mirrors the stable catalog facts — always check the current listing before ordering or a restock check.
| Field | Current Remy Peptides listing |
|---|---|
| Product page | SS-31 (Elamipretide) 10mg Vial |
| Format | 10mg · Lyophilized research vial |
| Stock status | In stock |
| AED price tier | See product page (currently around AED 250-300) |
| COA route | Check the product page and COA library; request lot-specific HPLC and identity documentation when a public batch file is not yet posted. |
| Use restriction | For in-vitro laboratory research only. Not for human or veterinary use. |
COA and Purity Checks for Research-Use Buyers
For Dubai and UAE research-supply searches, the cleanest buying checklist for SS-31 is identity-first and verification-heavy. Before comparing any SS-31 10mg source, confirm:
- The listing names the compound precisely — SS-31 / elamipretide, sequence D-Arg-Dmt-Lys-Phe-NH2 — and gives a stable product URL with vial size, format, price tier, and stock status.
- A lot-specific COA is available before purchase or on request, showing HPLC purity and an identity method (mass spec) tied to the lot number on the vial.
- The page states Research Use Only and avoids human-use, veterinary-use, diagnostic, therapeutic, or disease-management claims.
- Cold-chain handling and official-contact verification are clear enough to reduce impersonation and gray-market risk for a lyophilized peptide.
Remy Peptides centralizes that workflow through the product page, the COA library, and contact verification. For the regulatory framing that applies to research peptides locally, see Are research peptides legal in the UAE?
What This Page Does Not Claim
The research record helps define the compound, but it does not turn an RUO vial into a clinical product. Keep these boundaries in view:
- Avoid anti-aging, energy, athletic-performance, or organ-protection promises for any individual.
- Do not provide human-use instructions, dosing, or protocols.
- Do not imply that the Phase 2 trial program or the 2025 Forzinity (elamipretide HCl) approval for Barth syndrome makes a research-use vial a treatment for any condition.
Our Research Standards
This guide draws on the Remy SS-31 mitochondrial research profile, live product-catalog data, and peer-reviewed and official (FDA, journal) sources. No therapeutic, human-use, or veterinary-use claim is made. Read our editorial policy →
SS-31 10mg Research FAQ
Can Dubai researchers buy SS-31 10mg from Remy Peptides?
Yes. Remy Peptides lists SS-31 (elamipretide) 10mg Vial as in stock for research-use-only orders in Dubai and the UAE. The live product page is the source of truth for current stock, AED pricing, and COA request details.
What format and price does Remy list for SS-31 10mg?
Remy Peptides lists SS-31 10mg as 10mg · Lyophilized research vial, with current AED tiers shown around AED 250-300. Prices, pack tiers, and orderability can change, so the product page should be checked before any research order.
How should a researcher verify the COA and purity of an SS-31 vial?
Confirm the listing states the compound identity (SS-31 / elamipretide, sequence D-Arg-Dmt-Lys-Phe-NH2) and links to a lot-specific COA showing HPLC purity and identity (mass spec). When a public batch file is not yet posted for a given lot, request the lot-specific HPLC documentation from the supplier before any research order.
Is SS-31 10mg sold for human or veterinary use?
No. Remy Peptides products are supplied strictly for in-vitro laboratory research. They are not for human use, veterinary use, diagnosis, treatment, cure, disease management, or personal-use protocols.
Which page should researchers use next?
Use /product/ss-31-10mg for the live product facts, price tier, stock status, image, and COA route. Use the linked Remy SS-31 mitochondrial research profile for deeper cardiolipin-binding mechanism and trial-evidence context.
Sources
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250–1261. PMID: 23813215 ↑
- Roshanravan B, Liu SZ, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single treatment with elamipretide. PLOS ONE. 2021;16(7):e0253849. PMID: 34264994 ↑
- Reid Thompson W, Hornby B, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome. Genet Med. 2021;23(2):320–331. PMID: 33077895 ↑
- U.S. Food and Drug Administration. FDA grants accelerated approval for first treatment for Barth syndrome. 2025. fda.gov ↑
For current stock, pricing, and COA route, use the live SS-31 (Elamipretide) 10mg Vial page. For the full mechanism and trial dataset, continue to the SS-31 mitochondrial peptide research profile and official contact verification.